Woodcock Highlights US FDA Opioid Plans Amid Sen. Manchin And Others’ Criticisms
The statement outlining opioid priorities in the FDA’s FY 2022 budget request comes on the heels of Sen. Manchin’s criticism of the acting commissioner and FDA opioid policy.
You may also be interested in...
Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.